Bibliography
- PORTENOY RK, HAGEN NA: Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 41:273-281 (Abstract).
- PORTENOY RK, PAYNE D, JACOBSEN P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain (1999) 81:129-134 (Abstract).
- PORTENOY RK, BENNETT DS, RAUCK R et al.: Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J. Pain (2006) 7(8):583-591.
- DURFEE S, MESSINA J, KHANKARI R: Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am. J. Drug Deliv. (2006) 4(1):1-5.
- FARRAR JT, CLEARY J, RAUCK R et al.: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J. Natl. Cancer Inst. (1998) 90(8):611–616.
- PORTENOY RK, PAYNE R, COLUZZI P et al.: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain (1999) 79(2–3):303–312.
- DARWISH M, KIRBY M, ROBERTSON P, TRACEWELL W, JIANG JG: Comparative bioavailability of the novel fentanyl effervescent buccal tablet formulation: an open-label crossover study. J. Pain (2006) 7(4 Suppl. 4):S35 (Abstract).
- PATHER SI, SIEBERT JM, HONTZ J, KHANKARI RK, GUPTE SV, KUMBALE R. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Deliv. Tech. (2001) 1:54-57.
- TAYLOR D, PORTENOY R, MESSINA J, TREMMEL L: Fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-treated patients with cancer: a randomized, placebo-controlled study. J. Pain (2006) 7(4 Suppl. 2):S2 (Abstract).
- PORTENOY R, MESSINA J, NIEBLER G: Successful dose finding with fentanyl effervescent buccal tablets: combined results of open-label titration. J. Pain (2006) 7(4 Suppl. 4):S35 (Abstract).
- WEBSTER L, TAYLOR D, PEPPIN J, NIEBLER G: Open-label study of fentanyl effervescent buccal tablets in patients with noncancer pain and breakthrough pain: patient preference assessment. J. Pain (2006) 7(4 Suppl. 2):S52 (Abstract).
- SEGAL T, HALE M, JHANGIANI H, NALAMACHU S, NIEBLER G: Patients’ experience with fentanyl effervescent buccal tablets: Interim analysis of a long-term, multicenter, open-label study in cancer-related breakthrough pain. J. Pain (2006) 7(4 Suppl. 4):S35 (Abstract).
- HALE ME, WEBSTER LR, PEPPIN JF, MESSINA J: Open-label study of fentanyl effervescent buccal tablets in patients with chronic pain and breakthrough pain: interim safety and tolerability results. Program and Abstracts of the Annual Meeting of the American Academy of Pain Medicine, San Diego, USA (22 – 25 February 2006) (Abstract 120).
Websites
- http://transcripts.cnn.com/TRANSCRIPTS/0404/30/lol.02.html Perco-o-pops newest illegal drug fad in Philadelphia, USA. Live from CNN (aired 30 April 2004).
- http://opioids.com/fentanyl/perc-a-pop.html Lollipop drug hitting the streets. CNN, substance Abuse and Mental Health Services Administration cited as CNN source (27 April 2004).